A series of novel and potent inhibitors of the histone acetyltransferase monocytic zinc finger leukaemia proteinMOZ (MYST3, KAT6A) with potential application in treating cancers
[Detail]
|
Novel, highly potent peptide inhibitors of the Kv1.3 potassium channel, an emerging target for autoimmune diseases. The Monash peptides offer numerous advantages, including high Kv1.3 selectivity, minimising the potential for off-target side effects, efficacy across a range of experimental models an.....
[Detail]
|
